Healthcare [ 4/11 ] | Drug Manufacturers—Specialty & Generic [ 29/112 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 11, 23 | -0.69 Increased by +75.18% | -1.56 Increased by +35.75% |
| May 4, 23 | -1.43 Increased by 0.00% | -1.56 Increased by +5.34% |
| Mar 9, 23 | 0.57 Increased by +130.48% | 0.15 Increased by +1.87 K% |
| Nov 1, 22 | -0.57 Increased by +76.83% | -0.10 Decreased by -4.70 K% |
| Aug 4, 22 | -2.78 Decreased by -11.20% | -0.36 Decreased by -1.87 K% |
| Nov 9, 21 | -1.43 Decreased by -3.62% | -1.56 Increased by +5.34% |
| Aug 5, 21 | -1.87 Increased by +10.95% | -2.09 Increased by +5.04% |
| May 6, 21 | -2.46 Increased by +19.61% | -2.54 Increased by +1.24% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 23 | 22.26 M Decreased by -1.22% | -16.82 M Increased by +31.39% | Decreased by -75.59% Increased by +30.54% |
| Dec 31, 22 | 31.47 M Decreased by -14.86% | 19.14 M Increased by +193.08% | Increased by +60.83% Increased by +209.33% |
| Sep 30, 22 | 33.51 M Increased by +6.53% | -13.85 M Increased by +48.82% | Decreased by -41.34% Increased by +51.96% |
| Jun 30, 22 | 31.05 M Decreased by -2.31% | -46.68 M Decreased by -104.17% | Decreased by -150.34% Decreased by -109.00% |
| Mar 31, 22 | 22.53 M Decreased by -21.93% | -24.52 M Increased by +26.69% | Decreased by -108.82% Increased by +6.11% |
| Dec 31, 21 | 36.97 M Decreased by -3.13% | -20.57 M Increased by +75.23% | Decreased by -55.64% Increased by +74.44% |
| Sep 30, 21 | 31.46 M Decreased by -40.75% | -27.07 M Decreased by -468.46% | Decreased by -86.06% Decreased by -721.88% |
| Jun 30, 21 | 31.79 M Decreased by -5.45% | -22.86 M Decreased by -31.24% | Decreased by -71.93% Decreased by -38.81% |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.